BMRN vs. MTD: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at BMRN and MTD, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | BMRN | MTD |
|---|---|---|
| Company Name | BioMarin Pharmaceutical Inc. | Mettler-Toledo International Inc. |
| Country | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Biotechnology | Life Sciences Tools & Services |
| Market Capitalization | 10.64 billion USD | 27.07 billion USD |
| Exchange | NasdaqGS | NYSE |
| Listing Date | July 26, 1999 | November 14, 1997 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of BMRN and MTD by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | BMRN | MTD |
|---|---|---|
| 5-Day Price Return | 2.61% | 10.30% |
| 13-Week Price Return | -3.60% | 8.68% |
| 26-Week Price Return | -21.59% | 11.27% |
| 52-Week Price Return | -20.43% | -12.29% |
| Month-to-Date Return | 2.34% | 7.04% |
| Year-to-Date Return | -15.67% | 7.38% |
| 10-Day Avg. Volume | 2.09M | 0.15M |
| 3-Month Avg. Volume | 2.17M | 0.15M |
| 3-Month Volatility | 28.35% | 29.24% |
| Beta | 0.30 | 1.40 |
Profitability
Return on Equity (TTM)
BMRN
11.48%
Biotechnology Industry
- Max
- 97.92%
- Q3
- 11.99%
- Median
- -19.30%
- Q1
- -51.29%
- Min
- -132.03%
BMRN’s Return on Equity of 11.48% is on par with the norm for the Biotechnology industry, indicating its profitability relative to shareholder equity is typical for the sector.
MTD
1,675.84%
Life Sciences Tools & Services Industry
- Max
- 19.96%
- Q3
- 11.51%
- Median
- 6.47%
- Q1
- 3.86%
- Min
- -6.95%
MTD’s Return on Equity of 1,675.84% is exceptionally high, placing it well beyond the typical range for the Life Sciences Tools & Services industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.
Net Profit Margin (TTM)
BMRN
21.45%
Biotechnology Industry
- Max
- 73.34%
- Q3
- 18.98%
- Median
- -12.96%
- Q1
- -105.72%
- Min
- -259.82%
A Net Profit Margin of 21.45% places BMRN in the upper quartile for the Biotechnology industry, signifying strong profitability and more effective cost management than most of its peers.
MTD
21.46%
Life Sciences Tools & Services Industry
- Max
- 32.18%
- Q3
- 18.30%
- Median
- 10.19%
- Q1
- 4.20%
- Min
- -2.05%
A Net Profit Margin of 21.46% places MTD in the upper quartile for the Life Sciences Tools & Services industry, signifying strong profitability and more effective cost management than most of its peers.
Operating Profit Margin (TTM)
BMRN
25.33%
Biotechnology Industry
- Max
- 78.85%
- Q3
- 21.90%
- Median
- -13.30%
- Q1
- -109.94%
- Min
- -278.10%
An Operating Profit Margin of 25.33% places BMRN in the upper quartile for the Biotechnology industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
MTD
26.49%
Life Sciences Tools & Services Industry
- Max
- 38.39%
- Q3
- 21.40%
- Median
- 13.57%
- Q1
- 8.38%
- Min
- -3.51%
An Operating Profit Margin of 26.49% places MTD in the upper quartile for the Life Sciences Tools & Services industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
Profitability at a Glance
| Symbol | BMRN | MTD |
|---|---|---|
| Return on Equity (TTM) | 11.48% | 1,675.84% |
| Return on Assets (TTM) | 9.24% | 25.15% |
| Net Profit Margin (TTM) | 21.45% | 21.46% |
| Operating Profit Margin (TTM) | 25.33% | 26.49% |
| Gross Profit Margin (TTM) | 79.56% | 59.94% |
Financial Strength
Current Ratio (MRQ)
BMRN
5.56
Biotechnology Industry
- Max
- 16.97
- Q3
- 8.39
- Median
- 4.11
- Q1
- 2.64
- Min
- 0.74
BMRN’s Current Ratio of 5.56 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.
MTD
1.12
Life Sciences Tools & Services Industry
- Max
- 3.46
- Q3
- 2.78
- Median
- 1.91
- Q1
- 1.53
- Min
- 0.43
MTD’s Current Ratio of 1.12 falls into the lower quartile for the Life Sciences Tools & Services industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
Debt-to-Equity Ratio (MRQ)
BMRN
0.10
Biotechnology Industry
- Max
- 1.92
- Q3
- 0.79
- Median
- 0.12
- Q1
- 0.00
- Min
- 0.00
BMRN’s Debt-to-Equity Ratio of 0.10 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
MTD
81.23
Life Sciences Tools & Services Industry
- Max
- 1.35
- Q3
- 0.74
- Median
- 0.41
- Q1
- 0.18
- Min
- 0.00
With a Debt-to-Equity Ratio of 81.23, MTD operates with exceptionally high leverage compared to the Life Sciences Tools & Services industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.
Interest Coverage Ratio (TTM)
BMRN
-21.18
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.03
- Median
- -9.59
- Q1
- -65.05
- Min
- -163.11
BMRN has a negative Interest Coverage Ratio of -21.18. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
MTD
15.60
Life Sciences Tools & Services Industry
- Max
- 45.00
- Q3
- 27.84
- Median
- 7.16
- Q1
- 2.12
- Min
- -14.08
MTD’s Interest Coverage Ratio of 15.60 is positioned comfortably within the norm for the Life Sciences Tools & Services industry, indicating a standard and healthy capacity to cover its interest payments.
Financial Strength at a Glance
| Symbol | BMRN | MTD |
|---|---|---|
| Current Ratio (MRQ) | 5.56 | 1.12 |
| Quick Ratio (MRQ) | 3.60 | 0.67 |
| Debt-to-Equity Ratio (MRQ) | 0.10 | 81.23 |
| Interest Coverage Ratio (TTM) | -21.18 | 15.60 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
BMRN
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
BMRN currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
MTD
0.00%
Life Sciences Tools & Services Industry
- Max
- 1.41%
- Q3
- 0.65%
- Median
- 0.35%
- Q1
- 0.00%
- Min
- 0.00%
MTD currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio (TTM)
BMRN
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
BMRN has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
MTD
0.00%
Life Sciences Tools & Services Industry
- Max
- 113.14%
- Q3
- 61.34%
- Median
- 17.74%
- Q1
- 0.00%
- Min
- 0.00%
MTD has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | BMRN | MTD |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
Price-to-Earnings Ratio (TTM)
BMRN
16.21
Biotechnology Industry
- Max
- 40.44
- Q3
- 39.37
- Median
- 22.12
- Q1
- 15.76
- Min
- 3.48
BMRN’s P/E Ratio of 16.21 is within the middle range for the Biotechnology industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
MTD
32.64
Life Sciences Tools & Services Industry
- Max
- 75.35
- Q3
- 51.00
- Median
- 32.93
- Q1
- 25.27
- Min
- 1.43
MTD’s P/E Ratio of 32.64 is within the middle range for the Life Sciences Tools & Services industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
Price-to-Sales Ratio (TTM)
BMRN
3.48
Biotechnology Industry
- Max
- 92.67
- Q3
- 41.36
- Median
- 8.45
- Q1
- 4.46
- Min
- 0.97
In the lower quartile for the Biotechnology industry, BMRN’s P/S Ratio of 3.48 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
MTD
7.00
Life Sciences Tools & Services Industry
- Max
- 10.49
- Q3
- 6.43
- Median
- 4.66
- Q1
- 2.88
- Min
- 1.08
MTD’s P/S Ratio of 7.00 is in the upper echelon for the Life Sciences Tools & Services industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.
Price-to-Book Ratio (MRQ)
BMRN
1.75
Biotechnology Industry
- Max
- 22.72
- Q3
- 10.68
- Median
- 4.55
- Q1
- 2.44
- Min
- 0.59
BMRN’s P/B Ratio of 1.75 is in the lower quartile for the Biotechnology industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.
MTD
1,299.40
Life Sciences Tools & Services Industry
- Max
- 6.69
- Q3
- 5.00
- Median
- 3.46
- Q1
- 2.38
- Min
- 0.93
At 1,299.40, MTD’s P/B Ratio is at an extreme premium to the Life Sciences Tools & Services industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.
Valuation at a Glance
| Symbol | BMRN | MTD |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 16.21 | 32.64 |
| Price-to-Sales Ratio (TTM) | 3.48 | 7.00 |
| Price-to-Book Ratio (MRQ) | 1.75 | 1,299.40 |
| Price-to-Free Cash Flow Ratio (TTM) | 15.41 | 31.94 |